Litcius/Paper detail

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations

Patrick Neven, Sileny Han

2025Nature Reviews Clinical Oncology11 citationsDOI

Topics & Concepts

FulvestrantMedicineOncologyBreast cancerStage (stratigraphy)Internal medicineGynecologyCancerCancer researchEstrogen receptorBiologyPaleontologyProtein Degradation and InhibitorsAdvanced Breast Cancer TherapiesHistone Deacetylase Inhibitors Research
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations | Litcius